Fig. 1.
Aberrant METTL3 activation in lung tumors increases N6-methyladenosine modification and the protein expression of YAP. a, b The mRNA and protein levels of METTL3 were higher in human lung cancer tissues and cell lines. c Kaplan–Meier overall survival (OS) curves of METTL3 of human lung cancers. d, e The m6A levels of YAP from human lung cancer tissues determined by using MeRIP-qPCR (d) and cell lines (e) were higher than their normal adjacent lung tissues and control cell. f The interaction between METTL3 and YAP pre-mRNA was analyzed by RNA immunoprecipitation (RIP) assay. g The relative level of m6A in YAP from A549 cells with overexpression of METTL3 or knockdown of METTL3. h Putative m6A modification sites in the CDS sequence of YAP and synonymous mutations in the YAP CDS. i, j The m6A levels of YAP were detected in A549 cells with transfection of indicated genes. k The interaction between METTL3 and YAP pre-mRNA was analyzed by RIP. l The relative mRNA and protein levels of YAP in A549 cells with co-expressions of exogenous METTL3 and YAP-WT or YAP Muts#. m The mRNA and protein levels of METTL3, YAP, CTGF, and Cyr61 were detected in A549 cells. n, o Representative IHC staining images from human lung cancer tissue and their normal adjacent lung tissue for METTL3 and YAP. p Kaplan–Meier overall survival (OS) curves of YAP. Results were presented as mean ± SD of three independent experiments. *P < 0.05 or **P < 0.01 indicates a significant difference between the indicated groups. NS, not significant